|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Heuer R, Gill IS, Guazzoni G, Kirkali Z,
Marberger M, Richie JP and de la Rosette JJ: A critical analysis of
the actual role of minimally invasive surgery and active
surveillance for kidney cancer. Eur Urol. 57:223–232. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ritchie AW and Chisholm GD: The natural
history of renal carcinoma. Semin Oncol. 10:390–400.
1983.PubMed/NCBI
|
|
5
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC cancer staging manual. 7th.
Springer-Verlag; New York: pp. 547–560. 2009
|
|
6
|
Chin AI, Lam JS, Figlin RA and Belldegrun
AS: Surveillance strategies for renal cell carcinoma patients
following nephrectomy. Rev Urol. 8:1–7. 2006.PubMed/NCBI
|
|
7
|
Sun DW, Zhang YY, Sun XD, Chen YG, Qiu W,
Ji M and Lv GY: Prognostic value of cytokeratin 19 in
hepatocellular carcinoma: A meta-analysis. Clin Chim Acta.
448:161–169. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schmitt AM, Anlauf M, Rousson V, Schmid S,
Kofler A, Riniker F, Bauersfeld J, Barghorn A, Probst-Hensch NM,
Moch H, et al: WHO 2004 criteria and CK19 are reliable prognostic
markers in pancreatic endocrine tumors. Am J Surg Pathol.
31:1677–1682. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stathopoulos EN, Sanidas E, Kafousi M,
Mavroudis D, Askoxylakis J, Bozionelou V, Perraki M, Tsiftsis D and
Georgoulias V: Detection of CK-19 mRNA-positive cells in the
peripheral blood of breast cancer patients with histologically and
immunohistochemically negative axillary lymph nodes. Ann Oncol.
16:240–246. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Quackenbush EJ and Letarte M:
Identification of several cell surface proteins of non-T, non-B
acute lymphoblastic leukemia by using monoclonal antibodies. J
Immunol. 134:1276–1285. 1985.PubMed/NCBI
|
|
11
|
Wong SH, Hamel L, Chevalier S and Philip
A: Endoglin expression on human microvascular endothelial cells
association with betaglycan and formation of higher order complexes
with TGF-beta signalling receptors. Eur J Biochem. 267:5550–5560.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nassiri F, Cusimano MD, Scheithauer BW,
Rotondo F, Fazio A, Yousef GM, Syro LV, Kovacs K and Lioyd RV:
Endoglin (CD105): A review of its role in angiogenesis and tumor
diagnosis, progression and therapy. Anticancer Res. 31:2283–2290.
2011.PubMed/NCBI
|
|
13
|
Nair S, Nayak R, Bhat K, Kotrashetti VS
and Babji D: Immunohistochemical expression of CD105 and TGF-beta1
in oral squamous cell carcinoma and adjacent apparently normal oral
mucosa and its correlation with clinicopathologic features. Appl
Immunohistochem Mol Morphol. 24:35–41. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lytras D, Leontara V, Kefala M, Foukas PG,
Giannakou N, Pouliakis A, Dervenis C, Panayiotides IG and
Karakitsos P: Microvessel landscape assessment in pancreatic ductal
adenocarcinoma: Unclear value of targeting endoglin (CD105) as
prognostic factor of clinical outcome. Pancreas. 44:87–92. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sandlund J, Hedberg Y, Bergh A, Grankvist
K, Ljungberg B and Rasmuson T: Endoglin (CD105) expression in human
renal cell carcinoma. BJU Int. 97:706–710. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dubinski W, Gabril M, Iakovlev VV,
Scorilas A, Youssef YM, Faragalla H, Kovacs K, Rotondo F, Metias S,
Arsanious A, et al: Assessment of the prognostic significance of
endoglin (CD105) in clear cell renal cell carcinoma using automated
image analysis. Hum Pathol. 43:1037–1043. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Z and Yan X: CD146, a
multi-functional molecule beyond adhesion. Cancer Lett.
330:150–162. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sers C, Riethmuller G and Johnson JP:
MUC18, a melanoma-progression associated molecule, and its
potential role in tumor vascularization and hematogenous spread.
Cancer Res. 54:5689–5694. 1994.PubMed/NCBI
|
|
19
|
Takaha N, Taira E, Taniura H, Nagino T,
Tsukamoto Y, Matsumoto T, Kotani T, Sakuma S and Miki N: Expression
of gicerin in development, oncogenesis and regeneration of the
chick kidney. Differentiation. 58:313–320. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Taira E, Kohama K, Tsukamoto Y, Okumura S
and Miki N: Gicerin/CD146 is involved in neurite extension of
NGF-treated PC12 cells. J Cell Physiol. 204:632–637. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Harris L, Fritsche H, Mennel R, Norton L,
Ravdin P, Taube S, Somerfield MR, Hayes DF and Bast RC Jr; American
Society of Clinical Oncology, : American Society of Clinical
Oncology 2007 update of recommendations for the use of tumor
markers in breast cancer. J Clin Oncol. 25:5287–5312. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Saloustros E and Mavroudis D: Cytokeratin
19-positive circulating tumor cells in early breast cancer
prognosis. Future Oncol. 6:209–219. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
de Bono JS, Scher HI, Montgomery RB,
Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ
and Raghavan D: Circulating tumor cells predict survival benefit
from treatment in metastatic castration-resistant prostate cancer.
Clin Cancer Res. 14:6302–6309. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cohen SJ, Punt CJ, Iannotti N, Saidman BH,
Sabbath KD, Gabrail NY, Picus J, Morse MA, Mitchell E, Miller MC,
et al: Prognostic significance of circulating tumor cells in
patients with metastatic colorectal cancer. Ann Oncol.
20:1223–1229. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hou JM, Krebs MG, Lancashire L, Sloane R,
Backen A, Swain RK, Priest LJ, Greystoke A, Zhou C, Morris K, et
al: Clinical significance and molecular characteristics of
circulating tumor cells and circulating tumor microemboli in
patients with small-cell lung cancer. J Clin Oncol. 30:525–532.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lianidou ES, Markou A and Strati A: The
role of CTCs as tumor biomarkers. Adv Exp Med Biol. 867:341–367.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Volpe A and Patard JJ: Prognostic factors
in renal cell carcinoma. World J Urol. 28:319–327. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Aceto N, Bardia A, Miyamoto DT, Donaldson
MC, Wittner BS, Spencer JA, Yu M, Pely A, Engstrom A, Zhu H, et al:
Circulating tumor cell clusters are oligoclonal precursors of
breast cancer metastasis. Cell. 158:1110–1122. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yu XF, Yang HJ, Lei L, Wang C and Huang J:
CK19 mRNA in blood can predict non-sentinel lymph node metastasis
in breast cancer. Oncotarget. 7:30504–30510. 2016.PubMed/NCBI
|
|
30
|
Alix-Panabières C, Vendrell JP, Slijper M,
Pellé O, Barbotte E, Mercier G, Jacot W, Fabbro M and Pantel K:
Full-length cytokeratin-19 is released by human tumor cells: A
potential role in metastatic progression of breast cancer. Breast
Cancer Res. 11:R392009. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Smith SJ, Tilly H, Ward JH, Macarthur DC,
Lowe J, Coyle B and Grundy RG: CD105 (Endoglin) exerts prognostic
effects via its role in the microvascular niche of paediatric high
grade glioma. Acta Neuropathol. 124:99–110. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tanaka F, Otake Y, Yanagihara K, Kawano Y,
Miyahara R, Li M, Ishikawa S and Wada H: Correlation between
apoptotic index and angiogenesis in non-small cell lung cancer:
Comparison between CD105 and CD34 as a marker of angiogenesis. Lung
Cancer. 39:289–296. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nikiteas NI, Tzanakis N, Theodoropoulos G,
Atsaves V, Christoni Z, Karakitsos P, Lazaris AC, Papachristodoulou
A, Klonaris C and Gazouli M: Vascular endothelial growth factor and
endoglin (CD-105) in gastric cancer. Gastric Cancer. 10:12–17.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lei X, Guan CW, Song Y and Wang H: The
multifaceted role of CD146/MCAM in the promotion of melanoma
progression. Cancer Cell Int. 15:32015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang W, Yang ZL, Liu JQ, Jiang S and Miao
XY: Identification of CD146 expression, angiogenesis, and
lymphangiogenesis as progression, metastasis, and poor-prognosis
related markers for gallbladder adenocarcinoma. Tumour Biol.
33:173–182. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zabouo G, Imbert AM, Jacquemier J, Finetti
P, Moreau T, Esterni B, Birnbaum D, Bertucci F and Chabannon C:
CD146 expression is associated with a poor prognosis in human
breast tumors and with enhanced motility in breast cancer cell
lines. Breast Cancer Res. 11:R12009. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Koyama Y, Okayama H, Kumamoto K, Saito K,
Nakamura I, Ohki S and Takenoshita S: Overexpression of endoglin
(CD105) is associated with recurrence in radically resected gastric
cancer. Exp Ther Med. 1:627–633. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pires FR, Shih IeM, da Cruz Perez DE, de
Almeida OP and Kowalski LP: Mel-CAM (CD146) expression in parotid
mucoepidermoid carcinoma. Oral Oncol. 39:277–281. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Molnar B, Ladanyi A, Tanko L, Sréter L and
Tulassay Z: Circulating tumor cell clusters in the peripheral blood
of colorectal cancer patients. Clin Cancer Res. 7:4080–4085.
2001.PubMed/NCBI
|
|
40
|
Brandt B, Junker R, Griwatz C, Heidi S,
Brinkmann O, Semjonow A, Assmann G and Zanker KS: Isolation of
prostate-derived single cells and cell clusters from human
peripheral blood. Cancer Res. 56:4556–4561. 1996.PubMed/NCBI
|
|
41
|
Méhes G, Witt A, Kubista E and Ambros PF:
Circulating breast cancer cells are frequently apoptotic. Am J
Pathol. 159:17–20. 2001. View Article : Google Scholar : PubMed/NCBI
|
